PMID-10950816 – AOD9604 Oral Effects on Lipid Metabolism
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507.
Quick Reference
| Property | Value |
|---|---|
| PMID | 10950816 |
| DOI | 10.1152/ajpendo.2000.279.3.E501 |
| Year | 2000 |
| Journal | American Journal of Physiology – Endocrinology and Metabolism |
| Study Type | Animal in vivo + human tissue ex vivo |
| Evidence Level | V |
| Sample | ob/ob mice (30-day oral treatment); isolated human adipose tissue |
| Peptide(s) Studied | AOD-9604 |
Key Findings
- 30-day oral administration of AOD9604 significantly reduced body weight in ob/ob mice compared to vehicle controls
- AOD9604 exerted marked lipolytic activity on isolated human adipose tissue explants, demonstrating direct translational relevance
- Antilipogenic effects were observed — AOD9604 inhibited new fat synthesis in addition to promoting fat breakdown
- Oral bioavailability was confirmed over a chronic dosing period, supporting feasibility of oral peptide delivery
- The dual action (pro-lipolytic + anti-lipogenic) distinguishes AOD9604 from many single-mechanism anti-obesity compounds
Study Design
ob/ob mice received oral AOD9604 daily for 30 days with body weight tracked throughout. In a separate arm, human adipose tissue samples obtained from surgical procedures were incubated with AOD9604 ex vivo. Lipolysis was measured by glycerol release, and lipogenesis was assessed by incorporation of radiolabeled substrates into triglycerides.
Limitations
- ob/ob mouse model limitations (complete leptin deficiency) limit generalizability
- Human tissue experiments were ex vivo, not reflecting systemic pharmacokinetics or hormonal interactions
- Number of human tissue donors not specified in detail
- No plasma concentration measurements of AOD9604 after oral dosing
Clinical Relevance
This is the strongest translational study for AOD9604, bridging animal in vivo data with human tissue evidence. The demonstration of both lipolytic and antilipogenic activity on human adipose tissue provides the most compelling preclinical rationale for AOD9604 in obesity management. The dual mechanism suggests it could be effective even in patients where single-pathway agents have failed. The sustained oral bioavailability over 30 days further supports clinical development.
Related
#research #animal-in-vivo #AOD-9604 #evidence-level-V